Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation
Ist Teil von
The New England journal of medicine, 2014-05, Vol.370 (19), p.1781-1789
Ort / Verlag
Waltham, MA: Massachusetts Medical Society
Erscheinungsjahr
2014
Quelle
MEDLINE
Beschreibungen/Notizen
Letermovir is an antiviral with activity against CMV. In patients undergoing allogeneic hematopoietic-cell transplantation, the rate of prophylaxis failure with letermovir (240 mg per day) was 29%, as compared with 64% with placebo. Toxicity was similar for letermovir and placebo.
Cytomegalovirus (CMV) disease that results from CMV replication through reactivation or new infection is a serious, potentially life-threatening condition in immunocompromised patients. This is especially true for recipients of allogeneic hematopoietic-cell transplants
1
,
2
; CMV viremia occurs in 50 to 60% of these patients and may progress to CMV disease.
3
The standard of care for treatment of CMV infection or disease has typically been intravenous ganciclovir or its oral prodrug, valganciclovir, or alternatively, intravenous foscarnet or cidofovir.
4
Although efficacious, these therapies are associated with clinically significant drug-specific effects, including myelosuppression (neutropenia or thrombocytopenia with ganciclovir, valganciclovir, and cidofovir) and renal . . .